Diagnostic evaluation predicts sarcopenia in chronic kidney disease patients, suggesting important clinical implications.
Sarcopenia, defined as a decrease in muscle mass and strength, is prevalent among patients with chronic kidney disease (CKD) and is associated with adverse clinical outcomes. The ratio of creatinine- to cystatin C-based eGFR (eGFRcre/eGFRcys) and the serum creatinine-to-cystatin C ratio (sCre/sCys), which account for the influence of muscle mass, have been reported to be associated with sarcopenia. However, data concerning advanced CKD are limited, and no study has specifically examined this association in Japanese patients with CKD.
No takes yet. Share an insight, caveat, or question.
Hashimoto et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: